Palvella Therapeutics (PVLA) Earnings Analysis
Palvella Therapeutics (PVLA) next reports earnings on 2026-08-13, consensus EPS -1.16 USD. Last quarter (2026-05-07) it missed with EPS -1.2 USD vs -0.9 USD est (-33.3%). It has beaten estimates in 2/6 recent quarters (33%). Trailing P/E -34.10.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does PVLA next report earnings?
| Next earnings date | 2026-08-13 |
|---|---|
| Consensus EPS estimate | -1.16 USD |
| Revenue estimate | n/a |
PVLA earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-05-07 | -1.2 USD | -0.9 USD | -33.3% | Miss |
| 2026-03-31 | -1.08 USD | -0.91117 USD | -18.5% | Miss |
| 2025-08-14 | -0.86 USD | -0.78 USD | -10.3% | Miss |
| 2025-05-15 | -0.74 USD | -3.4 USD | +78.2% | Beat |
| 2025-03-31 | 4 USD | -0.39 USD | +1125.6% | Beat |
| 2024-08-14 | -2.76 USD | -2.4 USD | -15% | Miss |
Beat rate: 2/6 (33%) over reported quarters with consensus data.
PVLA valuation and analyst view
| Trailing P/E | -34.10 |
|---|---|
| Trailing EPS | -3.76737 USD |
| Price / book | 8.01 |
| Dividend yield | 0.00% |
| Market cap | 1.69B |
| Analyst consensus | Buy (11 buy / 0 hold / 0 sell) |
| Avg price target | 245 USD |
Related research pages
Frequently asked questions
When is Palvella Therapeutics (PVLA)'s next earnings date?
Palvella Therapeutics is next scheduled to report on 2026-08-13, with a consensus EPS estimate of -1.16 USD.
Did PVLA beat earnings last quarter?
In its 2026-05-07 report, PVLA posted EPS of -1.2 USD versus a -0.9 USD estimate — a miss of 33.3%.
What is PVLA's earnings track record?
Over the last 6 reported quarters with consensus data, PVLA beat estimates 2 times (33%).
What is PVLA's current P/E ratio and EPS?
PVLA trades at a trailing P/E of -34.10 on trailing EPS of -3.7673656128329327 USD.
What do analysts rate PVLA?
Analyst consensus is "Buy" across 11 ratings (1 strong buy, 10 buy, 0 hold, 0 sell, 0 strong sell). Average 12-month price target: 245 USD.